BRPI9810519B1 - derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. - Google Patents

derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Info

Publication number
BRPI9810519B1
BRPI9810519B1 BRPI9810519-1A BRPI9810519A BRPI9810519B1 BR PI9810519 B1 BRPI9810519 B1 BR PI9810519B1 BR PI9810519 A BRPI9810519 A BR PI9810519A BR PI9810519 B1 BRPI9810519 B1 BR PI9810519B1
Authority
BR
Brazil
Prior art keywords
homoerythromycin
deoxo
aza
derivatives
substituted
Prior art date
Application number
BRPI9810519-1A
Other languages
English (en)
Inventor
Brian Scott Bronk
Michael Anthony Letavic
Takushi Kaneko
Bingwei Vera Yang
Edward Alan Glazer
Hengmiao Cheng
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21959336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9810519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI9810519A publication Critical patent/BRPI9810519A/pt
Publication of BRPI9810519B1 publication Critical patent/BRPI9810519B1/pt
Publication of BRPI9810519B8 publication Critical patent/BRPI9810519B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9810519A 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. BRPI9810519B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4934897P 1997-06-11 1997-06-11
PCT/IB1998/000839 WO1998056802A1 (en) 1997-06-11 1998-05-29 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives

Publications (3)

Publication Number Publication Date
BRPI9810519A BRPI9810519A (pt) 2000-09-19
BRPI9810519B1 true BRPI9810519B1 (pt) 2012-02-22
BRPI9810519B8 BRPI9810519B8 (pt) 2022-11-16

Family

ID=21959336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810519A BRPI9810519B8 (pt) 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Country Status (49)

Country Link
US (4) US6420536B1 (pt)
EP (1) EP0988310B9 (pt)
JP (2) JP3315704B2 (pt)
KR (1) KR100396168B1 (pt)
CN (4) CN1793155B (pt)
AP (1) AP1231A (pt)
AR (1) AR013086A1 (pt)
AT (1) ATE251173T1 (pt)
AU (1) AU749816B2 (pt)
BG (1) BG64391B1 (pt)
BR (1) BRPI9810519B8 (pt)
CA (1) CA2293823C (pt)
CO (1) CO4950611A1 (pt)
CZ (1) CZ298556B6 (pt)
DE (2) DE69818665T2 (pt)
DK (1) DK0988310T3 (pt)
DZ (1) DZ2514A1 (pt)
EA (1) EA002441B1 (pt)
EG (1) EG24081A (pt)
ES (1) ES2205487T3 (pt)
FR (1) FR04C0013I2 (pt)
GT (1) GT199800077A (pt)
HN (1) HN1998000086A (pt)
HR (1) HRP980314B1 (pt)
HU (2) HU228005B1 (pt)
ID (1) ID22992A (pt)
IL (1) IL132809A0 (pt)
IS (1) IS1998B (pt)
LU (1) LU91076I9 (pt)
MA (1) MA24564A1 (pt)
ME (1) ME00876B (pt)
MY (1) MY123354A (pt)
NL (1) NL300150I2 (pt)
NO (1) NO316911B1 (pt)
NZ (2) NZ500660A (pt)
OA (1) OA11224A (pt)
PA (1) PA8452201A1 (pt)
PE (1) PE79699A1 (pt)
PL (1) PL191601B1 (pt)
PT (1) PT988310E (pt)
RS (1) RS49675B (pt)
SI (1) SI0988310T1 (pt)
SK (1) SK284171B9 (pt)
TN (1) TNSN98082A1 (pt)
TW (1) TW472060B (pt)
UA (1) UA67744C2 (pt)
UY (1) UY25040A1 (pt)
WO (1) WO1998056802A1 (pt)
ZA (1) ZA985017B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
EP1779853A3 (en) * 1997-09-10 2010-01-27 Merial Ltd. 9a-azalides as veterinary antimicrobial agents
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
DK1011689T3 (da) * 1997-09-10 2007-05-21 Merial Ltd Anvendelse af 9a-azalider som veterinære antimikrobielle midler
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
US6100240A (en) * 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
CA2292359C (en) * 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
CZ20014120A3 (cs) * 1999-05-18 2003-01-15 Pfizer Products Inc. Nové krystalické formy makrolidového antibiotika
EA200100983A1 (ru) * 1999-05-24 2002-10-31 Пфайзер Продактс Инк. Производные 13-метилэритромицина
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
PT1206476E (pt) * 1999-08-24 2006-05-31 Abbott Lab 9a-azalidos com actividade antibacteriana
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
US6608033B1 (en) 1999-08-27 2003-08-19 Pfizer Inc. Treatment or prevention of coccidiosis
MXPA02007305A (es) * 2000-01-27 2002-11-29 Pfizer Prod Inc Composiciones antiboticas de azalida.
CA2407448A1 (en) * 2000-04-27 2001-11-01 Pfizer Products Inc. The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
JP4104463B2 (ja) * 2001-04-27 2008-06-18 ファイザー・プロダクツ・インク ４’’−置換された−９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシン誘導体を製造するための方法
WO2003011266A2 (en) * 2001-08-01 2003-02-13 Pfizer Products Inc. Azalide antibiotic compositions
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
US20070141086A1 (en) * 2003-11-21 2007-06-21 Ohara Michael K Use of antibiotics as vaccine adjuvants
ATE557013T1 (de) * 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
EP1841437B1 (en) * 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) * 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) * 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
DK2550286T3 (en) 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
CN105198944B (zh) 2010-05-20 2018-06-01 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
CN103080121B (zh) * 2010-09-20 2015-11-25 瑞士诺华动物保健有限公司 用于制备在二脱氧甲基己糖环的C-4”处被环氧基团修饰的9-脱氧-9a-氮杂-9a-高红霉素A的新方法
CA2814333A1 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
CN102993250B (zh) * 2011-07-06 2016-02-10 洛阳惠中兽药有限公司 C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物
CN102260306B (zh) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 一种制备泰拉霉素的方法
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
CN102786569B (zh) * 2012-09-07 2016-12-07 安徽中升药业有限公司 泰拉霉素中间体及其制备方法与泰拉霉素的制备方法
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
WO2015014907A1 (en) * 2013-07-31 2015-02-05 Farma Grs, D.O.O. Process for preparation of tulathromycin
CN103497227B (zh) * 2013-09-13 2015-09-30 青岛科技大学 一种泰拉菌素中间体的制备方法
CN104725446B (zh) * 2015-03-26 2017-10-27 宁夏泰瑞制药股份有限公司 一种从泰拉霉素粗品中分离泰拉霉素a和泰拉霉素b的方法
CN104861018A (zh) * 2015-06-17 2015-08-26 瑞普（天津）生物药业有限公司 一种泰拉菌素的制备方法
CN105646617A (zh) * 2016-01-21 2016-06-08 杭州海尔希畜牧科技有限公司 一种制备泰拉霉素的方法
FR3048612B1 (fr) * 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
CN106046077B (zh) * 2016-08-04 2019-07-26 湖北美天生物科技股份有限公司 一种泰拉霉素a的合成方法
CN108003207B (zh) * 2017-12-19 2019-05-10 海门慧聚药业有限公司 制备泰拉霉素的方法
CN111087433B (zh) * 2018-10-23 2023-03-21 湖北美天生物科技股份有限公司 一种泰拉霉素中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
US5226958A (en) * 1991-04-11 1993-07-13 Pacemark, Inc. Sealant for pneumatic inner tubes and tubeless tires
EP0549040A1 (en) 1991-12-20 1993-06-30 Merck & Co. Inc. Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
UA70972C2 (uk) 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
CA2293823A1 (en) 1998-12-17
EG24081A (en) 2008-05-11
LU91076I9 (en) 2018-07-02
US20040023896A1 (en) 2004-02-05
CZ442199A3 (cs) 2000-07-12
ZA985017B (en) 1999-12-17
CN1172947C (zh) 2004-10-27
AU7347598A (en) 1998-12-30
ME00876B (me) 2012-06-20
CN1243766C (zh) 2006-03-01
HU228005B1 (en) 2012-08-28
HN1998000086A (es) 1999-03-08
NO996106D0 (no) 1999-12-10
SI0988310T1 (en) 2004-02-29
MA24564A1 (fr) 1998-12-31
CN1566129A (zh) 2005-01-19
IS5252A (is) 1999-11-16
EP0988310B1 (en) 2003-10-01
OA11224A (en) 2003-07-16
AU749816B2 (en) 2002-07-04
JP3315704B2 (ja) 2002-08-19
PT988310E (pt) 2003-12-31
RS49675B (sr) 2007-11-15
UA67744C2 (uk) 2004-07-15
CZ298556B6 (cs) 2007-11-07
KR100396168B1 (ko) 2003-08-27
NO316911B1 (no) 2004-06-21
CN1793155A (zh) 2006-06-28
US20040180842A1 (en) 2004-09-16
US6777393B2 (en) 2004-08-17
BRPI9810519B8 (pt) 2022-11-16
BG103945A (bg) 2000-07-31
FR04C0013I2 (pt) 2005-10-21
SK284171B9 (sk) 2005-03-04
JP2000514098A (ja) 2000-10-24
HK1028048A1 (en) 2001-02-02
AP9801255A0 (en) 1998-06-30
CN1793155B (zh) 2010-05-12
PA8452201A1 (es) 2000-05-24
TNSN98082A1 (fr) 2005-03-15
PE79699A1 (es) 1999-08-25
NZ500660A (en) 2002-03-01
ID22992A (id) 1999-12-23
HK1068893A1 (en) 2005-07-29
UY25040A1 (es) 2000-09-29
US6936592B2 (en) 2005-08-30
HUS1200028I1 (hu) 2016-08-29
DE122004000018I2 (de) 2011-01-13
GT199800077A (es) 1999-12-02
CO4950611A1 (es) 2000-09-01
IS1998B (is) 2005-03-15
MY123354A (en) 2006-05-31
NO996106L (no) 2000-02-10
NL300150I2 (nl) 2004-09-01
HUP0002209A3 (en) 2003-05-28
HUP0002209A2 (hu) 2000-12-28
YU58699A (pt) 2002-08-12
CA2293823C (en) 2004-02-17
WO1998056802A1 (en) 1998-12-17
HK1088014A1 (zh) 2006-10-27
LU91076I2 (fr) 2004-07-05
HRP980314A2 (en) 1999-04-30
IL132809A0 (en) 2001-03-19
DE69818665T2 (de) 2004-04-29
DE69818665D1 (de) 2003-11-06
JP2002316933A (ja) 2002-10-31
EA002441B1 (ru) 2002-04-25
PL337505A1 (en) 2000-08-28
DK0988310T3 (da) 2003-12-15
ATE251173T1 (de) 2003-10-15
BG64391B1 (bg) 2004-12-30
EP0988310A1 (en) 2000-03-29
EA199901015A1 (ru) 2000-06-26
ES2205487T3 (es) 2004-05-01
HRP980314B1 (en) 2004-04-30
FR04C0013I1 (pt) 2004-06-11
CN1259136A (zh) 2000-07-05
NL300150I1 (nl) 2004-08-02
DZ2514A1 (fr) 2003-02-01
SK284171B6 (sk) 2004-10-05
CN101691390A (zh) 2010-04-07
NZ514871A (en) 2003-08-29
DE122004000018I1 (de) 2004-09-30
SK168399A3 (en) 2000-11-07
BRPI9810519A (pt) 2000-09-19
US20020061858A1 (en) 2002-05-23
KR20010013632A (ko) 2001-02-26
TW472060B (en) 2002-01-11
AP1231A (en) 2003-12-11
US6420536B1 (en) 2002-07-16
AR013086A1 (es) 2000-12-13
EP0988310B9 (en) 2006-03-08
PL191601B1 (pl) 2006-06-30

Similar Documents

Publication Publication Date Title
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
ATE187063T1 (de) Arzneimittel
ID24654A (id) Formulasi farmasi omeprazola
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
ID20053A (id) Hipolipidemat 1,4-benzotiazepin-1,1-dioksida
IS5425A (is) Læknislyf
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
ATE367150T1 (de) Arzneimittel
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO980546D0 (no) Farmasöytiske midler
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
EE9900545A (et) Farmatseutiline kompositsioon
BR9811582B1 (pt) compostos derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, medicamento e composição farmacêutica contendo os mesmos.
BR9507768A (pt) Composição farmacêutica
ID29294A (id) Komposisi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
FI973229L (fi) Uusi farmaseuttinen koostumus
ID25857A (id) Komposisi farmasi
FI961364L (fi) Lääkeainekoostumus
MA26481A1 (fr) Derives d'arylsecocholadiene
NO306672B1 (no) N,N-dietyl-8,8-dipropyl-2-azaspiro[4,5]decan-2-propanamindimaleat, farmasöytisk blanding omfattende forbindelsen samt anvendelse derav
ID23531A (id) Komposisi farmasi
BR1100929A (pt) Derivados 1,2-difenilpirrol e uma composição farmacêutica
BR1100391A (pt) Composto e composição farmacêutica

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B25C Requirement related to requested transfer of rights

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 860150304618 DE 23/12/2015, E NECESSARIO E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO DE CESSAO, CONFORME ART. 18 DO DEC. 13.609/43.

B25A Requested transfer of rights approved
B25G Requested change of headquarter approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2635 DE 06/07/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.02.2022

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS, PARA MATERIA RELATIVA A PRODUTOS E PROCESSOS COM APLICACAO VETERINARIA. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.